References

  1. Public announcement to TB in vitro diagnostics manufacturers, procurement agencies and national TB programmes on inclusion of WHO prequalification for TB in vitro diagnostics. Geneva: World Health Organization; 2021 (https://extranet.who.int/pqweb/sites/default/files/documents/210211_ PublicAnnouncement_TB_%20in-vitro-diagnostics.pdf).
  2. Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH et al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol. 2020;122:142–52 (https://pubmed.ncbi.nlm.nih.gov/32058069/).
  3. Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol. 2020;122:129–41 (https://pubmed.ncbi.nlm.nih.gov/32060007/).
  4. McMaster University. GRADEpro GDT [website]. 2020 (https://gradepro.org/).
  5. Starshinova A, Zhuravlev V, Dovgaluk I, Panteleev A, Manina V, Zinchenko U et al. A comparison of intradermal test with recombinant tuberculosis allergen (diaskintest) with other immunologic tests in the diagnosis of tuberculosis infection. International Journal of Mycobacteriology. 2018;7(1):32.
  6. Starshinova A, Zinchenko Y, Istomina E, Basantsova N, Filatov M, Belyaeva E et al. [Diagnosis of latent tuberculosis infection in personnel of various institutions and determination of the risk group for tuberculosis]. Bioprep Prev Diagnosis. Treat. 2019;19:178–84.
  7. Aggerbeck H, Ruhwald M, Hoff ST, Borregaard B, Hellstrom E, Malahleha M et al. C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial. PLoS One. 2018;13(9):e0204554 (https://www.ncbi.nlm.nih.gov/pubmed/30248152).
  8. Aggerbeck H, Ruhwald M, Hoff S, Tingskov P, Hellstrom E, Malahleha M et al. Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial. Int J Tuberc Lung Dis. 2019;23(1):38–44.
  9. Ruhwald M, Aggerbeck H, Gallardo RV, Hoff ST, Villate JI, Borregaard B et al. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon gamma release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respir Med. 2017;5(4):259–68 (https://www.ncbi.nlm.nih.gov/pubmed/28159608).
  10. Hoff ST, Peter JG, Theron G, Pascoe M, Tingskov PN, Aggerbeck H et al. Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. Eur Respir J. 2016;47(3):919–28 (https://www.ncbi.nlm.nih.gov/pubmed/26677940).
  11. Streltsova E, Ryzhkova O, Bespalova A. Comparative clinical studies of skin test Diaskintest and Mantoux test in patients with pulmonary tuberculosis. Astrakhan Medical Journal. 2011;6(1):265–70.
  12. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J et al. Predictive value of interferon-y release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45–55 (https://pubmed.ncbi.nlm.nih.gov/21846592/)
  13. Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P et al. Interferon-y release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014;189(1):77–87 (https://pubmed.ncbi.nlm.nih. gov/24299555/)
  14. Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384(9944):682–90 (https://pubmed.ncbi.nlm.nih.gov/24835842/)
  15. Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M et al. The tuberculin skin test versus QuantiFERON TB Gold® in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One. 2011;6(3):e17984 (https://pubmed.ncbi.nlm.nih.gov/21479236/).
  16. Mathad JS, Bhosale R, Balasubramanian U, Kanade S, Mave V, Suryavanshi N et al. Quantitative IFN-γ and IL-2 response associated with latent tuberculosis test discordance in HIV-infected pregnant women. Am J Respir Crit Care Med. 2016;193(12):1421–8 (https://pubmed.ncbi.nlm.nih. gov/26765255/)
  17. McCarthy KM, Scott LE, Gous N, Tellie M, Venter WD, Stevens WS et al. High incidence of latent tuberculous infection among South African health workers: an urgent call for action. Int J Tuberc Lung Dis. 2015;19(6):647–53 (https://pubmed.ncbi.nlm.nih.gov/25946353/)
  18. Sharma SK, Vashishtha R, Chauhan LS, Sreenivas V, Seth D. Comparison of TST and IGRA in diagnosis of latent tuberculosis infection in a high TB-burden setting. PLoS One. 2017;12(1):e0169539 (https:// pubmed.ncbi.nlm.nih.gov/28060926/).
  19. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8(3):e1001012 (https://pubmed. ncbi.nlm.nih.gov/21445325/).

Book navigation